FDA Classifies Special Baby Sleep System as Class II
Published Date: 6/26/2026
Rule
Summary
The FDA has officially placed the infant supine sleep system into class II, meaning it now has special safety rules but fewer regulatory hurdles. This change helps make sure the device is safe and effective while making it easier for companies to bring these helpful baby sleep products to market. The new classification took effect on June 26, 2026, but has been in place since March 30, 2023, so manufacturers and parents can breathe easy!
Analyzed Economic Effects
4 provisions identified: 2 benefits, 1 costs, 1 mixed.
Infant sleep system reclassified to Class II
The FDA has classified the infant supine sleep system as Class II (special controls). This classification is codified at 21 CFR 880.5690, became applicable on March 30, 2023, and the final order is effective June 26, 2026.
510(k) premarket notification still required
Infant supine sleep systems are subject to premarket notification under section 510(k) of the Federal Food, Drug, and Cosmetic Act unless FDA grants an exemption under section 510(m). This classification remained applicable on March 30, 2023 and the final order is effective June 26, 2026.
New testing, data, and warning label rules
The special controls require clinical data and postmarket surveillance, human factors testing, biocompatibility, non-clinical performance testing (including tipping and cleaning compatibility), and specific labeling. Labeling must include a prominent warning that the device has not been demonstrated to reduce SIDS/SUID and must provide instructions for fit, cleaning, and safe sleep practices.
De Novo classification creates predicate for future devices
Because the device was classified via the De Novo process, the infant supine sleep system can serve as a predicate device for future substantially equivalent devices, allowing future sponsors to use the less burdensome 510(k) pathway rather than De Novo or premarket approval.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-19704, Robotically-Assisted Surgical Devices-Premarket Submissions; Draft Guidance for Industry and Food and Drug Administration Staff; Availability
The FDA just dropped a draft guide for companies making robot-assisted surgical devices, showing how to get their products approved before selling. If you’re in the biz, now’s the time to check it out and send your feedback by November 24, 2026. This guide aims to make the approval process clearer and smoother, potentially saving time and money down the road.
2026-19655, Jeffrey Thies: Final Debarment Order
Jeffrey Thies is banned for 10 years from importing any drugs into the U.S. because he was convicted of trafficking fake drugs. He didn’t respond to the FDA’s notice, so the ban started on September 25, 2026. He can apply to end the ban anytime, but until then, no drug imports for him!
Previous / Next Documents
Previous: 2026-12904, Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs Syndrome
The FDA has officially placed the external lower leg nerve stimulator for Restless Legs Syndrome into a safer, easier-to-get category called Class II. This change helps patients get access to this helpful device faster while keeping safety in check. The new rules took effect on June 26, 2026, and could lower costs by cutting some red tape for makers and users alike.
Next: 2026-12913, Cinnamaldehyde in Pesticide Formulations; Exemption From the Requirement for a Tolerance
The EPA just made life easier for farmers and pesticide makers by saying cinnamaldehyde (a cinnamon-smelling ingredient) doesn’t need a strict residue limit when used in pesticides—up to 100 parts per million. This rule kicks in on June 26, 2026, saving time and money by cutting red tape. If anyone wants to object, they have until August 25, 2026, to speak up.